About 200 reports

In 2015, Sandoz received FDA approval for Zarxio, a biosimilar version of filgrastim for all the same indications as branded filgrastim.

  • Drug Discovery And Development
  • World
  • Amgen Inc.
  • Daiichi Sankyo Company
  • Eli Lilly & Co.

Filgrastim or Lenograstim or CSF##), Interleukin ## (Cytokine Synthesis Inhibitory Factor or CISF or IL##), Interleukin ## (IL##), Interleukin ## (IL##), Interleukin ## (IL##), Interleukin ## (B Cell Stimulatory Factor ## or Binetrakin or Lymphocyte Stimulatory Factor ## or Pitrakinra or IL##),

  • Clinical Trial
  • Drug Discovery And Development
  • World
  • Product Initiative
  • Pfizer Inc.
  • Clinical Trial profile. 7 Trial Title
  • Clinical Trial profile. 140 Trial Title
  • Clinical Trial
  • Drug Discovery And Development
  • Leukemia
  • World
  • Product Initiative
  • Blood Supply
  • Drug Discovery And Development
  • Prostate Cancer
  • Therapy
  • OncBioMune Pharmaceuticals, Inc.
  • Clinical Trial profile. 153 Trial Title
  • PROMINENT DRUGS

filgrastim ## cyclophosphamide ## docetaxel (piperacillin sodium + tazobactam sodium) (piperacillin + tazobactam) Total Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2017 2017 trials are taken as of August 2017 ##

  • Clinical Trial
  • Drug Discovery And Development
  • Filgrastim
  • World
  • Amgen Inc.
  • Name

s Zarxio (filgrastim-sndz), in the U. S.

  • Clinical Trial
  • Drug Discovery And Development
  • World
  • Market Size
  • Medidata
  • Clinical Trial profile. 140 Trial Title
  • Clinical Trial profile. 422 Trial Title
  • Cancer
  • Drug Discovery And Development
  • United States
  • World
  • Product Initiative

The FDA requires that the biosimilar INN is followed by a four letter suffix, denoting the product manufacturer name, such as filgrastim-sndz in the case of the filgrastim TABLE ##: TRASTUZUMAB BIOSIMILARS, 2017 ##. ##. ## NOMENCLATURE biosimilar by Sandoz.

  • Drug Discovery And Development
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • Clinical Trial profile. 161 Trial Title
  • Clinical Trial profile. 223 Trial Title

filgrastim; sargramostim Fred Hutchinson Cancer Research Center ## Mar 1995 ## Oct 1997 ## ## Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Collaborato

  • Biological Therapy
  • Blood Disease
  • Drug Discovery And Development
  • World
  • Product Initiative

Gallbladder Cancer Global Clinical Trials Review, H##, 2017 HEA LTH CA REHEA LTH CA RE REFERENCE CODE: GDHC##CTIDB PUBLICATION DATE: AUG 2017 LIST OF TABLES Gallbladder Cancer Global Clinical Trials Review, H##, 2017 outlines clinical trials in Gallbladder Cancer.

  • Chemotherapy
  • Clinic
  • Clinical Trial
  • Drug Discovery And Development
  • Eli Lilly & Co.
  • 10.2 NORTH AMERICA

FDA approval of Novartis' s biosimilar filing for its filgrastim biosimilar.

  • Drug Discovery And Development
  • World
  • genOway SA
  • Horizon Discovery
  • Taconic Biosciences, Inc.
  • AMYOTROPHIC LATERAL SCLEROSIS THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017*
  • Prominent Drugs

filgrastim ## FLX-## ## ibudilast ## Total Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2017 2017 trials are taken as of March 2017 ## Latest Clinical Trials News on Amyotrophic Lateral Sclerosis MAR ##, 2017: CO

  • Clinical Trial
  • Dementia
  • Drug Discovery And Development
  • World
  • Product Initiative
  • Clinical Trial profile. 153 Trial Title
  • Clinical Trial profile. 34 Trial Title
  • Chemotherapy
  • Clinical Trial
  • Drug Discovery And Development
  • United States
  • World
  • Untitled
  • NIH Research Festival Exhibit

FDA approval of Novartis' s biosimilar filing for its filgrastim biosimilar.

  • Drug Discovery And Development
  • Charles River Laboratories International, Inc.
  • genOway SA
  • Horizon Discovery
  • Taconic Biosciences, Inc.
  • Clinical Trial profile. 90 Trial Title
  • Clinical Trial profile. 98 Trial Title

filgrastim; melphalan Boston Medical Center National Institutes of Health ## Nov 2000 ## Jun 2005 ## ## ## ## ## DNA Synthesis Inhibitor DNA A Multicenter Phase II Trial of Bortezomib (Velcade), Melphalan and Dexamethasone (V-MD) in Patients with Symptomatic AL-Amyloidosis or Light Chain Depo

  • Clinical Trial
  • Drug Discovery And Development
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 918 Trial Title
  • Clinical Trial profile. 671 Trial Title

Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation GDCT## NCT##, Immunology Graft Versus Host Disease (GVHD) Completed Phase III Interventional

  • Drug Discovery And Development
  • Pharmaceutical
  • Transplantation
  • United States
  • World
  • Clinical Trial profile. 703 Trial Title
  • Clinical Trial profile. 75 Trial Title
  • Clinical Trial
  • Drug Discovery And Development
  • Leukemia
  • United States
  • World
  • Clinical Trial profile. 104 Trial Title
  • Clinical Trial profile. 133 Trial Title

Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors GDCT## NCT##, UC-##; ##-CC-##; NCT## Immunology Hematopoiet

  • Blood Supply, Tissue Banking And Transplantation
  • Clinical Trial
  • Drug Discovery And Development
  • World
  • Product Initiative

filgrastim neuregulin-## Preclinical Preclinical Preclinical Preclinical Recombinant protein Recombinant protein Antisense Oligonucleotide Small molecule Granulocyte Colony Stimulating Factor Receptor Agonist Undisclosed Undisclosed Undisclosed SPH-## STMX-## HL-## MP-## lisinopril V-##

  • Drug Discovery And Development
  • World
  • Market Size
  • Novartis AG
  • Sanofi S.A.
  • Clinical Trial profile. 139 Trial Title
  • Clinical Trial profile. 609 Trial Title

filgrastim; fludarabine phosphate; melphalan; natural killer cells; rituximab; T cell-depleted hematopoietic stem cells; thiotepa St.

  • Drug Discovery And Development
  • Monoclonal Antibody
  • Pharmaceutical
  • United States
  • World

filgrastim; prednisone; rituximab; vincristine The Alliance for Clinical Trials in Oncology Montefiore Medical Center ## May 2005 ## May 2018 ## ## ## ## ## Cytotoxic To Cells Expressing B Lymphocyte Antigen CD## (B Lymphocyte Surface Antigen B## or Bp## or Leukocyte Surface Antigen Leu ##

  • Drug Discovery And Development
  • Lymphoma
  • Monoclonal Antibody
  • United States
  • World
  • Clinical Trial profile. 392 Trial Title
  • Clinical Trial profile. 256 Trial Title
  • Drug Discovery And Development
  • Monoclonal Antibody
  • United States
  • World
  • Celgene Corporation
  • Clinical Trial profile. 763 Trial Title
  • Clinical Trial profile. 659 Trial Title
  • Cancer
  • Drug Discovery And Development
  • United States
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

Filgrastim or Lenograstim or CSF##), Interleukin ## (T Cell Growth Factor or Aldesleukin or IL##)) Terminated Phase I/ II Interventional aldesleukin; allogeneic natural killer cells; cyclophosphamide; fludarabine phosphate; rituximab Masonic Cancer Center National Cancer Institute US ## Ja

  • Drug Discovery And Development
  • Leukemia
  • Lymphoma
  • United States
  • World

Filgrastim Biosimilar Biosimilar Ipsen S. A.

  • Drug Discovery And Development
  • World
  • Market Size
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Clinical Trial profile. 685 Trial Title
  • Clinical Trial profile. 750 Trial Title

filgrastim; melphalan; methylprednisolone; mycophenolate mofetil; umbilical cord blood Masonic Cancer Center National Cancer Institute ## Oct 1999 ## Jul 2009 ## ## ## Feasibility Study of Using G-CSF Stimulated Bone Marrow and In Vivo T-cell Depletion in Patients with Hematologic Malignancie

  • Drug Discovery And Development
  • Immunology
  • Pharmaceutical
  • World
  • Product Initiative
  • Clinical Trial profile. 243 Trial Title
  • Clinical Trial profile. 334 Trial Title

filgrastim German CLL Study Group Amgen Inc ## Jul 1999 ## Sep 2003 ## ## ## ## ## Granulocyte Colony Stimulating Factor Receptor (CD## or GCSFR or CSF##R) Agonist Granulocyte Colony Stimulating Factor Receptor (CD## or GCSFR or CSF##R) Clinical Trial profile. ## Trial Title Trial Identifier

  • Clinical Trial
  • Drug Discovery And Development
  • Leukemia
  • United States
  • World
  • Clinical Trial profile. 246 Trial Title
  • Clinical Trial profile. 49 Trial Title

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients with Newly Diagnosed or Relapsed/ Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes GDCT## NCT##, NCI-2013-##; ##. ##; P##CA##; CDR##; ## Oncology Acute My

  • Drug Discovery And Development
  • Leukemia
  • World
  • Product Initiative
  • Celgene Corporation
  • Clinical Trial profile. 624 Trial Title
  • Clinical Trial profile. 402 Trial Title
  • Clinical Trial
  • Drug Discovery And Development
  • Pharmaceutical
  • Stroke
  • World
  • Clinical Trial profile. 71 Trial Title

filgrastim; granulocyte colony-stimulating factor; haploidentical natural killer cells; melphalan; Monoclonal Antibody to Inhibit GD## for Oncology St.

  • Cancer
  • Clinical Trial
  • Drug Discovery And Development
  • World
  • Product Initiative